AKP 11

Drug Profile

AKP 11

Alternative Names: AKP-11

Latest Information Update: 23 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Akaal Pharma
  • Class Anti-inflammatories; Antipsoriatics; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Plaque psoriasis; Rheumatoid arthritis
  • Preclinical Actinic keratosis; Crohn's disease; Multiple sclerosis; Ulcerative colitis

Most Recent Events

  • 02 May 2018 Phase-II clinical trials in Rheumatoid arthritis in Australia (Topical) (ACTRN12617001223325)
  • 28 Aug 2017 Akaal Pharma plans a phase II trial for Rheumatoid arthritis in Australia (Topical) (ACTRN12617001223325)
  • 12 Jul 2017 Phase-II clinical trials in Atopic dermatitis in Australia (Topical) (ACTRN12617000763347)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top